Rita De Sanctis1, Alexia Bertuzzi2, Umberto Basso3, Alessandro Comandone4, Silvia Marchetti5, Andrea Marrari5, Piergiuseppe Colombo6, Romano Fabio Lutman7, Laura Giordano8, Armando Santoro5. 1. Department of Oncology-Haematology, Humanitas Cancer Center, IRCCS, Milan, Italy rita.de_sanctis@cancercenter.humanitas.it. 2. Department of Oncology-Haematology, Humanitas Cancer Center, IRCCS, Milan, Italy Department of Medical Oncology, Adelaide & Meath Hospital, incorporating the National Children's Hospital (AMNCH), Dublin, Ireland. 3. Medical Oncology Unit 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy. 4. Department of Oncology, Gradenigo Hospital, Turin, Italy. 5. Department of Oncology-Haematology, Humanitas Cancer Center, IRCCS, Milan, Italy. 6. Department of Pathology, Humanitas Cancer Center, IRCCS, Milan, Italy. 7. Department of Radiology, Humanitas Cancer Center, IRCCS, Milan, Italy. 8. Biostatics Unit, Humanitas Cancer Center, IRCCS, Milan, Italy.
Abstract
BACKGROUND/AIM: Non-pegylated liposomal doxorubicin (NPLD) has demonstrated antitumour activity equivalent to conventional doxorubicin and a significantly lower risk of cardiotoxicity. This phase II trial was performed to evaluate the activity and the safety of NPLD and ifosfamide combination in patients with metastatic soft tissue sarcoma. PATIENTS AND METHODS: Thirty-four patients received NPLD 40 mg/m(2) (d1) and ifosfamide 3 g/m(2)/day (d1-3) every three weeks as first-line therapy of metastatic soft tissue sarcoma. The treatment was planned for a maximum of six cycles. RESULTS: The objective response (OR) rate among response-assessable patients was 55.9%. The median progression-free survival (PFS) was 4.2 months and the median overall survival (OS) was 11.2 months. Symptomatic grade 3 cardiotoxicity occurred in one patient (3%). CONCLUSION: The combination of NPLD and ifosfamide reported in a population of metastatic soft tissue sarcoma patients at risk for developing heart failure encourage antitumour activity, similar to that of classical doxorubicin. Copyright
BACKGROUND/AIM: Non-pegylated liposomal doxorubicin (NPLD) has demonstrated antitumour activity equivalent to conventional doxorubicin and a significantly lower risk of cardiotoxicity. This phase II trial was performed to evaluate the activity and the safety of NPLD and ifosfamide combination in patients with metastatic soft tissue sarcoma. PATIENTS AND METHODS: Thirty-four patients received NPLD 40 mg/m(2) (d1) and ifosfamide 3 g/m(2)/day (d1-3) every three weeks as first-line therapy of metastatic soft tissue sarcoma. The treatment was planned for a maximum of six cycles. RESULTS: The objective response (OR) rate among response-assessable patients was 55.9%. The median progression-free survival (PFS) was 4.2 months and the median overall survival (OS) was 11.2 months. Symptomatic grade 3 cardiotoxicity occurred in one patient (3%). CONCLUSION: The combination of NPLD and ifosfamide reported in a population of metastatic soft tissue sarcomapatients at risk for developing heart failure encourage antitumour activity, similar to that of classical doxorubicin. Copyright
Authors: Matteo M Trucco; Christian F Meyer; Katherine A Thornton; Preeti Shah; Allen R Chen; Breelyn A Wilky; Maria A Carrera-Haro; Lillian C Boyer; Margaret F Ferreira; Umber Shafique; Jonathan D Powell; David M Loeb Journal: Clin Sarcoma Res Date: 2018-11-05
Authors: Paula Martínez-Delgado; Serena Lacerenza; Antonia Obrador-Hevia; Maria Lopez-Alvarez; José L Mondaza-Hernandez; Elena Blanco-Alcaina; Paloma Sanchez-Bustos; Nadia Hindi; David S Moura; Javier Martin-Broto Journal: Cells Date: 2020-06-10 Impact factor: 6.600